All Cosmos Bio-Tech Holding Corporation

Total Valuation

All Cosmos Bio-Tech Holding Corporation carries a market capitalization of 2.07B, placing it among publicly traded companies globally. Its enterprise value stands at 2.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

All Cosmos Bio-Tech Holding Corporation currently has 67.24M shares outstanding.

Valuation Ratios

All Cosmos Bio-Tech Holding Corporation trades at a trailing price-to-earnings ratio of 16.88. The price-to-sales ratio is 0.88, and the price-to-book ratio stands at 1.62.

Enterprise Valuation

On an enterprise value basis, All Cosmos Bio-Tech Holding Corporation trades at an EV/EBITDA multiple of 7.32 and an EV/FCF ratio of 7.24. The EV/Sales ratio of 0.75 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.32 provides insight into valuation relative to core operating earnings.

Financial Position

All Cosmos Bio-Tech Holding Corporation maintains a current ratio of 4.99, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.07, indicating elevated leverage, while an interest coverage ratio of 20.90 demonstrates strong ability to service its debt obligations.

Financial Efficiency

All Cosmos Bio-Tech Holding Corporation posts a return on equity of 10.60 and a return on invested capital of 5.80.

Taxes

Over the trailing twelve months, All Cosmos Bio-Tech Holding Corporation has paid 91.14M in income taxes, reflecting an effective tax rate of 30.65.

Stock Price Statistics

All Cosmos Bio-Tech Holding Corporation's stock has declined approximately -22.77847% over the past 52 weeks. The 50-day moving average sits at 33.15, while the 200-day moving average is 37.67.

Income Statement

Over the trailing twelve months, All Cosmos Bio-Tech Holding Corporation generated 2.95B in revenue and converted that into 153.00M in net income, yielding earnings per share of 3.05. EBITDA reached 303.66M, while operating income came in at 303.66M.

Balance Sheet

All Cosmos Bio-Tech Holding Corporation holds 1.44B in cash and equivalents against 381.29M in total debt, resulting in a net debt position of -649.08M. Total book value stands at 1.60B, with working capital of 2.45B providing operational flexibility.

Cash Flow

All Cosmos Bio-Tech Holding Corporation produced 253.00M in operating cash flow over the past twelve months. After subtracting -43.86M in capital expenditures, free cash flow totaled 209.14M - equivalent to 3.10 per share.

Margins

All Cosmos Bio-Tech Holding Corporation operates with a gross margin of 28.13, reflecting its pricing power and cost economics. The operating margin of 10.30 and net profit margin of 5.19 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

All Cosmos Bio-Tech Holding Corporation's most recent stock split took place on August 14, 2025 with a 20:21 split ratio.

Scores

All Cosmos Bio-Tech Holding Corporation posts an Altman Z-Score of 3.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.